GVBL

The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Genomic Valley latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%

Companies resources are allocated to majorly productive assets like Plant & Machinery and unproductive assets like Capital Work in Progress, Inventory, Accounts Receivable, Short Term Loans & Advances

Balance sheet of Genomic Valley is strong. It shouldn't have solvency or liquidity issues.

The profit is oscillating. The profit of Genomic Valley is ₹0.02 Crs for Mar 2024, ₹0.65 Crs for Mar 2023 and -₹0.01 Crs for Mar 2022

The debt of Genomic Valley is decreasing. Latest debt of Genomic Valley is -₹0.42 Crs as of Sep-24. This is less than Mar-24 when it was -₹0.01 Crs.

Genomic Valley is not expensive. Latest PE of Genomic Valley is 50.07, while 3 year average PE is 112. Also latest EV/EBITDA of Genomic Valley is 48.77 while 3yr average is 100.

Genomic Valley has given better returns compared to its competitors. Genomic Valley has grown at ~97.74% over the last 1yrs while peers have grown at a median rate of 34.81%

Promoters seem not to be bullish about the company and have been selling shares in the open market. Latest quarter promoter holding in Genomic Valley is 46.83% and last quarter promoter holding is 54.67%

There is Insufficient data to gauge this.